ABOSHealthcare · BiotechnologyThe 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +199.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 15 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Acumen Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (83): Sales and profits are climbing, and climbing faster than before.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +199.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Mar 2026 | BTIG | Reiterates | Buy | $8.00 |
| 16 Mar 2026 | BTIG | Maintains | Buy | — |
| 27 Jan 2026 | BTIG | Maintains | Buy | — |
| 18 Nov 2025 | B of A Securities | Maintains | Buy | — |
| 25 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 17 June 2025 | Citigroup | Initiates | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | UBS | Maintains | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | UBS | Maintains | Buy | — |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 July 2024 | Citigroup | Initiates | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2024 | UBS | Maintains | Buy | — |
| 27 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Dec 2023 | Deutsche Bank | Initiates | Buy | — |
| 9 Aug 2023 | Credit Suisse | Reiterates | Outperform | — |
| 9 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 July 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABOS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 32% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 11% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| ABOSAcumen Pharmaceuticals, Inc. | $192.8M | 42 |
| KRROKorro Bio, Inc. | $191.5M | 29 |
| VYGRVoyager Therapeutics, Inc. | $194.9M | 74 |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $186.9M | 26 |
| KROSKeros Therapeutics, Inc. | $199.1M | 68 |
| ORMPOramed Pharmaceuticals, Inc. | $183.7M | 75 |
| DTILPrecision BioSciences, Inc. | $205.1M | 70 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Acumen Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Acumen Pharmaceuticals, Inc. (ABOS) released its Q2 2026 earnings call transcript, as published on Seeking Alpha. The item consists of the transcript of the company's second-quarter earnings call.
Why it matters — A transcript of the Q2 2026 earnings call gives ABOS watchers direct access to management's commentary on the company's recent results and outlook.
Acumen Pharmaceuticals confirmed it is on track to release top-line results from its Phase II ALTITUDE-AD study of sabirnetug in late 2026 during its Q2 earnings call.
Why it matters — The timeline update provides ABOS watchers with clarity on the expected readout date for the company's lead Alzheimer's candidate, a key catalyst for the stock.
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease, reported its financial results for the second quarter of 2026 and provided a business update.
Why it matters — ABOS watchers would track this report for the latest financial and operational update on the company's ongoing Alzheimer's disease development programs.
Acumen Pharmaceuticals announced it will report second quarter financial results on Wednesday, Aug. 12, 2026, and will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Why it matters — ABOS watchers will be able to hear the company's latest business and financial update on a scheduled date for the second quarter.
The article examines how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed relative to their sector so far this year.
Why it matters — Investors tracking ABOS would want to know how its stock performance compares to both a peer and the broader medical sector over the same period.
The 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Acumen Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acumen Pharmaceuticals, Inc. 42 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Acumen Pharmaceuticals, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +199.6% from the last close, and Ticker Nerd's factor model ranks Acumen Pharmaceuticals, Inc. 42 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Acumen Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Acumen Pharmaceuticals, Inc. returned +90.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript". Acumen Pharmaceuticals, Inc. (ABOS) released its Q2 2026 earnings call transcript, as published on Seeking Alpha. The item consists of the transcript of the company's second-quarter earnings call.
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s work centers on disease-modifying approaches aimed at what it identifies as key underlying biological drivers of neurodegeneration in Alzheimer’s patients. Acumen Pharmaceuticals’ lead drug candidate, ACU193, is a monoclonal antibody designed to selectively target amyloid-beta oligomers, a soluble and potentially toxic form of amyloid believed to play a central role in cognitive decline. The company is advancing ACU193 through clinical programs such as ALTITUDE-AD and INTERCEPT-AD, which evaluate safety, biomarker effects, and cognitive outcomes across different stages of the disease. Headquartered in Newton, Massachusetts and founded in 1996, Acumen Pharmaceuticals operates within the broader neuroscience and central nervous system therapeutics space, contributing to ongoing efforts to address a major unmet medical need in global healthcare markets.
CEO Mr. Daniel J. O'Connell M.B.A. · 60 employees · United States · https://acumenpharm.com